trial

Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia

NCTId NCT02647437
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 18 (actual)
Sponsored by University of Colorado, Denver
Primary completion 2024-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
18 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2013-06
Primary completion
2024-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Levetiracetam

Sponsors

University of Colorado, DenverLead Sponsor

Investigators

1
Jason Tregellas, Ph.D.Principal Investigator

Sites

1 total
Aurora, United States

Facts & assertions

4 sourced
Enrollment
18
Phase
NA
Primary Completion Date
2024-09
Status
COMPLETED
relationships
The graph out of here
drug
Levetiracetam
drug
lead_sponsor
University of Colorado, Denver
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jason Tregellas, Ph.D.
person